Abstract 1852P
Background
Oncology is a satisfying career. Helping patients through their cancer diagnosis and treatment can offer a sense of self fulfilment. But on the other hand, it can take its emotional toll on doctors. Long hours, dealing with life and death can affect oncologist’s mental health. It can cause depression, anxiety and PTSD. Our aim is to identify individuals who are at risk for burnout and facilitate interventions to prevent it.
Methods
This study used a descriptive design to identify individuals at risk for burnout among oncologists. It included 100 clinicians, working in various hospitals in Tunisia, recruited via email invitations. Inclusion criteria included being a practicing oncologist with at least one year of experience. Participants anonymously completed the Maslach Burnout Inventory (MBI) questionnaire, a tool used to detect burnout. The MBI consists of 22 items that assess emotional exhaustion, depersonalization, and personal accomplishment.
Results
The population is made of 77% females and 23% males. With an average age of 33 years, medical oncologists represented 80%, radiotherapists 12% and surgical oncologists 8%. The majority had professional experience ranging from 1 to 5 years. Gender difference was seen on the emotional exhaustion subscale where women scored higher. No significant differences were observed in the scores based on professional experience or field of practice. Emotional Exhaustion: Participants had a mean score of 29. Meaning the participants experienced high levels of emotional exhaustion. Only 20% of the population had low score, 20% scored moderately and 60% had high scores. Depersonalization: Results showed a mean score of 10. Participants are experiencing moderate levels of depersonalization, with 28% scoring low, 32% scoring moderate and 40% scoring high. Personal Accomplishment: the average score was 35. Participants are experiencing moderate levels of personal accomplishment, with 32% at low risk of burnout, 20% at moderate risk and 48% at high risk of burnout.
Conclusions
Our study provides valuable information about the levels of burnout experienced by oncologists. It should inform interventions and strategies to mitigate burnout and promote wellbeing in this population. It should also ring alarm bells to oncologists’ suffering mental health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05